Global Guidance for Dyslipidaemia Management in Adults: A Scoping Review
Global Heart · 16.12.2025 · 20 (1) · 111
DOI: 10.5334/gh.1506 ↗Kurz gefasst
Scoping Review in der Zeitschrift Global Heart, online erschienen am 16.12.2025. Verfasst von Andrew E Moran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Irving Medical Center, New York, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Disease Management, Dyslipidemias, Hypolipidemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Objective
Dyslipidaemia is a leading preventable cause of global cardiovascular disease (CVD) burden, responsible for over four million deaths each year (1). A scoping review took a worldwide perspective and assessed recent World Health Organization (WHO) guidance documents, other national or regional guidelines, and randomized controlled trial evidence supporting dyslipidaemia management best practices.
Methods
Review of WHO guidance documents included aspects of dyslipidaemia management, but none provided a detailed and comprehensive approach. Of 11 non-WHO national or regional dyslipidaemia guidelines, nine met pre-defined inclusion criteria and were reviewed in depth. Structured electronic searches of MEDLINE found 27 systematic reviews of randomized clinical trials supporting dyslipidaemia management guideline priority topics.
Findings
This scoping review found overall consistency in the recommendations of regional and national dyslipidaemia guideline recommendations. Guidelines varied in terms of approach to assessing patient CVD risk and recommendations to treat with non-statin lipid-lowering therapy (LLT). Robust randomized trial evidence supports that a dyslipidaemia management guideline focuses on priority areas including approach to patient selection for LLT efficacy and safety, selection of initial LLT drugs and dose intensity, timing of LLT monitoring, and LLT management in specific high-risk groups (familial hypercholesterolemia, diabetes, chronic kidney disease, HIV and other inflammatory diseases, and older adults). Few regional or national guidelines provided practical implementation recommendations or cost-effectiveness assessments; less clinical trial evidence was found for the priority topic of equitable treatment.
Conclusion
Taking a global perspective, this scoping review describes the scope and depth of the current evidence base informing best practice management of dyslipidaemia for the primary and secondary prevention of CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia University Irving Medical Center, New York, USA.
- Resolve to Save Lives, New York, USA.
- World Health Organization, Geneva, Switzerland.
- McMaster University, Hamilton, Canada.
ORCID-Profile: Andrew E Moran, Ashish Krishna, Lawrence Mbuagbaw, Kouamivi M Aboyibor, Rauell J Santos
Förderung
- World Health Organization
Zitieren
APA
Moran, A. E., Krishna, A., Mbuagbaw, L., Aboyibor, K. M., & Santos, R. J. (2025). Global Guidance for Dyslipidaemia Management in Adults: A Scoping Review. Global Heart, 20(1), 111. https://doi.org/10.5334/gh.1506
Vancouver
Moran AE, Krishna A, Mbuagbaw L, Aboyibor KM, Santos RJ. Global Guidance for Dyslipidaemia Management in Adults: A Scoping Review. Global Heart. 2025;20(1):111. doi:10.5334/gh.1506
BibTeX
@article{Moran2025,
author = {Moran, Andrew E and Krishna, Ashish and Mbuagbaw, Lawrence and Aboyibor, Kouamivi M and Santos, Rauell J},
title = {Global Guidance for Dyslipidaemia Management in Adults: A Scoping Review},
journal = {Global Heart},
year = {2025},
volume = {20},
number = {1},
pages = {111},
doi = {10.5334/gh.1506}
}
EUVIMED